26 May 2015
A new study has identified a novel biomarker, which could play a key role in controlling chemotherapy resistance among patients with the most common form of ovarian cancer.
Researchers at the University of Texas MD Anderson Cancer Center looked at miR-506 and determined it could serve as a clinical marker for epithelial ovarian cancer chemotherapy. It is hoped the biomarker could also work as a potential therapy due to its ability to make cancer cells more vulnerable to chemotherapy.
Published in the Journal of the National Cancer Institute, the study included data from the Cancer Genome Atlas and other independent clinical populations. The team noted "statistically significant improved responses" to the chemotherapy drugs cisplatin and olaparib when miR-506 was added to the treatment.
"MiR-506 was associated with better response to therapy and longer progression-free and overall survival," said Wei Zhang, professor of pathology at the Cancer Center.
Epithelial ovarian cancer accounts for approximately 90 per cent of all ovarian cancers.
Professor Zang added that chemoresistance is a major challenge in cancer treatment and this study may provide a means to overcome resistance.
Posted by Phillip Briggs
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.